Crispr therapeutics presents data at the 2024 american society of hematology (ash) annual meeting

-preliminary data demonstrate that ctx112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol-

ASH Ratings Summary

ASH Quant Ranking